Aptamer Group launches targeted radiopharmaceutical program
Three therapeutic targets selected across high‑value clinical indications pipeline planned for four radiotherapy assets with in vivo data expected by end of 2026
Three therapeutic targets selected across high‑value clinical indications pipeline planned for four radiotherapy assets with in vivo data expected by end of 2026
Programme to focus on advancement of animal-replacement technologies and transition towards human-first, AI-driven drug discovery
Your trusted source for online, expert led clinical CE/CPD activities in 2026
This guest editorial explores how emerging AI tools are significantly enhancing the utility of flow cytometry across life sciences and highlights how industry leaders must work together to overcome challenges
The Elecsys ApoE4 test eliminates the need for confirmatory genetic testing in the significant proportion of Alzheimer’s patients who do not carry the ApoE4 variant
Multiplex PCR assay enables beverage microbiology labs to accelerate product release testing by up to six days
Novel RUO tests can help scientists understand neurological function and disease progression
Against a backdrop of rising global obesity, researchers trace brown fat to an unexpected embryonic source